|
Where do you come from? http://www.ismef.it/stmap_3f470.html?cialis.revia.ibuprofen.rizatriptan irina clinica braila The ratings reflect the existence of the market (market presence) Sinarmas MSIG issignificant in Indonesia, the healthy operating performance and capitalizationstrong business profile. The ratio of risk-based capitalization (RBC) Sinarmas MSIGreached 562% at the end of 2012, well above the minimum requirement of 120%.The company continues to face challenges in improving the sustainability premiumdue to single premium (premium singular) dominate the business portfolio.
|